PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6764095

[Acute leukemia].

T Takubo·H Shibata·T Masaoka
View original source ↗Export metadata ↓

Abstract

Recent progress in the treatment of acute leukemia is so rapid and wide-ranged that it is difficult to detail the progress. Therefore we limit this paper focusing following items: 1) FAB classification and therapeutic response; 2) 5000 leukocyte differential and survival; 3) bone marrow transplantation; and 4) over all survival and 5-year survival. 1) FAB classification and therapeutic response: 59 cases of acute non-lymphocytic leukemia were classified according to FAB classification: (M5-16 cases. The differences in the complete remission rate, duration of remission and median survival were not significant among these groups. 2) 5000 leukocyte differential and survival: 86 cases with acute leukemia which achieved complete remission were divided into three groups according to the levels of remaining leukemic cells by 5000 leukocyte differential: 0-1/5000-39 cases, 2-4/5000-24 cases and 5-/5000-23 cases. A close correlation between the leukemic cell level during remission and survival of patients was observed. A marked tendency of longer survival was observed in cases in which leukemic cells decreased during remission and vice versa. 3) Bone marrow transplantation (BMT) therapy: Up to now, 15 patients have been treated and 4 of them are alive now. The longest survival is a case of a 9 year old boy with ALL, who is doing well after BMT for one year and a half. 4) Median survival and 5-year survival: Overall median survival of acute leukemia patients was 7 months (1970-1974) and 12 months (1975-1979). We have experienced 12 patients of 5-year survivors. Out of them, 7 patients are still in remission for more than 6 years. The 5-year survival rate was 0.5% before 1969, and 8.3% after 1970. This indicates a remarkable improvement in the treatment of acute leukemia.

Explore related subjects

Acute DiseaseAdultBone Marrow TransplantationCell SurvivalFemaleHumansLeukemiaLeukocyte CountMaleMiddle AgedEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T Takubo, H Shibata, T Masaoka. 1982. [Acute leukemia].. https://pubmed.ncbi.nlm.nih.gov/6764095/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

Hallucinations in the acute schizophrenic-type psychosis: effects of gender and age of illness onset.

Our objective was to test the hypothesis that gender, the age of illness onset, or the interaction between these two variables, would distinguish acutely ill schizophrenic and schizoaffective patients who hallucinated from those who did not. Hallucinatory experiences were measured by the hallucination item of the Brief Psychiatric Rating Scale in a sample of 160 drug-free inpatients admitted for the treatment of an acute episode. Patients were categorized as either non-hallucinators or hallucinators. An additional analysis included only those who had 'severe' hallucinations (i.e., score > or = 5). Female gender, but not age of onset, predicted a higher frequency of hallucinations (irrespective of degree of severity) in the total sample, but specifically in the schizophrenic patients. These results indicate that there may be gender differences in the propensity to experience hallucinations during the acute schizophrenic episode.

Acute Disease↗
PubMed1999

Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

Internal tandem duplication of the FLT3 gene and point mutations of the N-RAS gene are the most frequent somatic mutations causing aberrant signal-transduction in acute myeloid leukemia (AML). However, their prognostic importance is unclear. In this study, their prognostic significance was analyzed in 201 newly diagnosed patients with de novo AML except acute promyelocytic leukemia. Three patients had mutations in both genes, 43 had only the FLT3 gene mutation, 25 had only the N-RAS gene mutation, and 130 had neither. These mutations seemed to occur independently. Both mutations were related to high peripheral white blood cell counts, and the FLT3 gene mutation was infrequently observed in the French-American-British (FAB)-M2 type. AML cases with wild FLT3/mutant N-RAS had a lower complete remission (CR) rate than those with wild FLT3/wild N-RAS, whereas the presence of mutant FLT3 did not affect the CR rate. Univariate analysis showed that unfavorable prognostic factors for overall survival were age 60 years or older (P =.0002), cytogenetic data (P =.002), FAB types other than M2 (P =.002), leukocytosis over 100 +/- 10(9)/L (P =.003), and the FLT3 gene mutation (P =.004). However, the N-RAS gene mutation was only a marginal prognostic factor (P =.06). For the subjects under 60 years old, multivariate analysis showed that the FLT3 gene mutation was the strongest prognostic factor (P =.008) for overall survival. The FLT3 gene mutation, whose presence is detectable only by genomic polymerase chain reaction amplification and gel electrophoresis, might serve as an important molecular marker to predict the prognosis of patients with AML.

Acute Disease↗